Drug Price Trends for KONVOMEP

Average Pharmacy Cost for KONVOMEP

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
KONVOMEP 2-84 MG/ML ORAL SUSP	65628-0272-10	1.21723	ML	2025-01-01
KONVOMEP 2-84 MG/ML ORAL SUSP	65628-0270-10	1.21723	ML	2025-01-01
KONVOMEP 2-84 MG/ML ORAL SUSP	65628-0272-03	2.02772	ML	2025-01-01
KONVOMEP 2-84 MG/ML ORAL SUSP	65628-0270-03	2.02772	ML	2025-01-01
KONVOMEP 2-84 MG/ML ORAL SUSP	65628-0270-05	1.73607	ML	2025-01-01

Market Analysis and Price Projections for Konvomep

Introduction to Konvomep

Konvomep, a recent addition to the proton pump inhibitors (PPIs) market, is an oral suspension formulation of omeprazole and sodium bicarbonate. Approved by the U.S. Food and Drug Administration (FDA) in September 2022, it is designed to treat active benign gastric ulcers and reduce the risk of upper gastrointestinal bleeding in critically ill patients, particularly those who have difficulty swallowing solid oral dose forms[1][4][5].

Market Context: Proton Pump Inhibitors

The global proton pump inhibitors market is experiencing steady growth, driven by factors such as the prevalence of gastroesophageal reflux disease (GERD), peptic ulcer disease, an aging population, and changing lifestyles. The market is projected to grow from $3.3 billion in 2023 to $4.12 billion by 2028 at a compound annual growth rate (CAGR) of 4.6%[1][3].

Market Segmentation and Konvomep's Position

In the proton pump inhibitors market, omeprazole, the active ingredient in Konvomep, holds a significant market share. As of 2022, omeprazole captured around 28.5% of the global market[3].

Konvomep's unique formulation as an oral suspension addresses a specific need for patients who struggle with swallowing tablets or capsules. This niche positioning is expected to contribute to its market traction, especially in regions like the United States, which is forecasted to lead the market with a significant share[3].

Price and Cost Analysis

The cost for Konvomep oral suspension varies based on the quantity and pharmacy. For instance, a 90-milliliter supply costs around $194, with prices ranging from $2.15 per milliliter for a 90-milliliter supply to $1.26 per milliliter for a 300-milliliter supply[2].

Market Drivers

Several factors are driving the adoption of Konvomep:

• Patient Need: The drug's liquid formulation fills a critical gap for patients who have difficulty swallowing solid oral dose forms, making it a valuable option for chronically ill patients[4][5].
• Regulatory Approval: The FDA approval in September 2022 has validated the safety and efficacy of Konvomep, boosting its market credibility[1][5].
• Strategic Marketing: Azurity Pharmaceuticals' focus on patient education and strategic marketing is expected to increase awareness and adoption of Konvomep[1].

Market Trends and Strategies

The proton pump inhibitors market, including Konvomep, is influenced by several trends:

• Integration with Digital Health Solutions: There is a growing trend towards integrating PPIs with digital health solutions to enhance patient compliance and monitoring[1].
• Global Market Expansion: Companies are expanding their reach into emerging markets, which is expected to drive growth for Konvomep[1].
• Focus on Gastrointestinal Health Education: Increased awareness and education about gastrointestinal health are likely to increase the demand for effective treatments like Konvomep[1].

Forecast and Growth Projections

Given the overall growth of the proton pump inhibitors market, Konvomep is expected to contribute significantly to this expansion. Here are some key projections:

• Market Size: The global proton pump inhibitors market is expected to reach $4.9 billion by 2033, growing at a CAGR of 5.2%[3].
• Konvomep's Contribution: While specific revenue projections for Konvomep are not detailed, its unique formulation and FDA approval position it for significant market share within the PPI segment[1][5].

Challenges and Restraints

Despite the positive outlook, there are challenges that Konvomep and the broader PPI market may face:

• High Inflation: Economic factors such as high inflation could impact the affordability and accessibility of Konvomep[1].
• Regulatory Updates: Continuous regulatory scrutiny and safety measures may influence the market dynamics[1].
• Environmental Impact: Increasing focus on environmental sustainability could affect the production and distribution of pharmaceuticals, including Konvomep[1].

Key Takeaways

• Market Growth: The proton pump inhibitors market, including Konvomep, is expected to grow steadily driven by increasing demand and innovative formulations.
• Unique Formulation: Konvomep's oral suspension formulation addresses a critical need for patients with swallowing difficulties.
• Price and Cost: The drug's cost varies but is generally around $194 for a 90-milliliter supply.
• Market Drivers: FDA approval, patient need, and strategic marketing are key drivers for Konvomep's adoption.
• Forecast: The market is projected to reach $4.9 billion by 2033, with Konvomep expected to contribute to this growth.

FAQs

Q: What is Konvomep used for? Konvomep is used to treat active benign gastric ulcers and to lower the risk of upper gastrointestinal bleeding in critically ill patients, particularly those who have difficulty swallowing solid oral dose forms[4][5].

Q: How much does Konvomep cost? The cost for Konvomep oral suspension is around $194 for a 90-milliliter supply, depending on the pharmacy[2].

Q: Who approved Konvomep? Konvomep was approved by the U.S. Food and Drug Administration (FDA) in September 2022[1][5].

Q: What is the market outlook for proton pump inhibitors? The global proton pump inhibitors market is expected to grow at a CAGR of 5.2% to reach $4.9 billion by 2033[3].

Q: Why is Konvomep significant in the market? Konvomep's unique liquid formulation addresses the need for patients who struggle with swallowing tablets or capsules, making it a valuable addition to the proton pump inhibitors market[4][5].

Cited Sources

1. The Business Research Company: Global Proton Pump Inhibitors Market Report 2024
2. Drugs.com: Konvomep Prices, Coupons, Copay Cards & Patient Assistance
3. Future Market Insights: Proton Pump Inhibitors Market Share & Forecast by 2033
4. Drug Topics: FDA-Approved Konvomep Releases To Public
5. Pharmaceutical Technology: US FDA grants approval for Azurity's Konvomep to treat gastric ulcer